Pharmaceutical Technology

APRIL 3, 2023

The latest guidance applies to the current phase of the pandemic and reflects the impact of the Omicron variant, which has led to high levels of immunity in all age groups through both vaccination efforts and infections across the globe.

Vaccination 278

Vaccination Vaccine 278

Bio Pharma Dive

MARCH 7, 2024

Early results from a Phase 1 study suggest the drug, amycretin, could be as potent as injectable medicines already sold by Novo and rival Eli Lilly.

Trials 287

Trials Medicine Drugs 287

Bio Pharma Dive

AUGUST 30, 2022

The biotech's drug prospect vopratelimab has become the latest member of a group of medicines targeting a molecule called ICOS to fall short of expectations in clinical testing.

Medicine 164

Medicine Drugs 164

Drug Discovery World

APRIL 9, 2024

The latest DDW Sitting Down With sponsored vodcast is now available. The post Watch the latest DDW vodcast appeared first on Drug Discovery World (DDW). It features Dr Adriano Flora, Director of Business Development at The Jackson Laboratory (JAX). In 2011, he returned to Europe and joined a global model generation service provider.

Business Development 52

Business Development Development Drugs Medicine 52

Pharmaceutical Technology

JANUARY 3, 2024

A new report from Novotech delves into the multifaceted landscape of HIV, focusing on its impact, treatment, and global initiatives.

Clinical Trials 295

Clinical Trials Clinical Trials Trials Research 295

Bio Pharma Dive

JULY 6, 2023

Five years after helping launch Allogene Therapeutics, Pfizer is backing another developer of “off-the-shelf” cell therapies in a deal that gives the drugmaker the chance to acquire a multiple myeloma treatment.

Development 327

Development 327

pharmaphorum

NOVEMBER 15, 2023

Elucid’s $80m round heads latest digital health financings Phil.Taylor Wed, 15/11/2023 - 08:17 Bookmark this

110

110

Bio Pharma Dive

MARCH 6, 2024

A small partnership with Merus adds to Gilead’s string of cancer dealmaking, which, so far, has not paid off for the large biotech.

Drugs 188

Drugs 188

Bio Pharma Dive

APRIL 12, 2023

For an upfront payment of $75 million, Novo gets an exclusive license to use Aspect Biosystems’ “bioprinting” technology to develop as many as four treatments for the diseases.

Licensing 305

Licensing Licensing Development 305

Bio Pharma Dive

DECEMBER 13, 2023

The company is now expecting to save $4 billion by the end of 2024, with a majority of the spending cuts coming from drug research and development.

Sales 280

Sales Development Drugs Research 280

Bio Pharma Dive

APRIL 4, 2024

The offering keeps new biotech stock offerings on their strongest pace in three years, accompanying an uptick in private company funding.

Drugs 164

Drugs 164

Bio Pharma Dive

MAY 31, 2023

The biotech, best known for its success developing migraine medicines, will seek approval of a treatment that failed a Phase 3 trial but showed signs of a positive effect.

Trials 310

Trials Medicine Drugs Development 310

Bio Pharma Dive

JULY 17, 2023

Leaders from the firm said that, despite a turbulent biotech market, most of their existing limited partners returned to participate in the new fund, which will support approximately a dozen startups.

Marketing 236

Marketing 236

pharmaphorum

OCTOBER 25, 2023

OrbiMed raises $4.3bn for latest biotech funds Phil.Taylor Wed, 25/10/2023 - 08:33 Bookmark this

103

103

Rethinking Clinical Trials

JULY 20, 2023

Listen to the latest podcast episode on SoundCloud or Apple Podcasts. The post July 20, 2023: Latest Podcast Episode Features BeatPain Utah’s Julie Fritz appeared first on Rethinking Clinical Trials. Adrian Hernandez about partnering with community health centers in the BeatPain Utah study.

Clinical Trials 100

Clinical Trials Clinical Trials Nurses Trials 100

Bio Pharma Dive

MAY 10, 2023

While some see the new donanemab results as adding to a “watershed moment” in Alzheimer’s research, others say they reinforce the limitations of so-called anti-amyloid therapies.

Doctors 286

Doctors Doctor Drugs Research 286

Pharma Times

JANUARY 13, 2023

Company becomes the latest member of the ABPI and galvanises the company’s UK connections

135

135

Bio Pharma Dive

NOVEMBER 29, 2022

At a medical conference, the companies detailed clinical trial results that could help support approval of their drug, lecanemab. However, some doctors aren’t yet convinced the medicine’s risks are worth its potential benefits.

Doctors 358

Doctors Doctor Drugs Clinical Trials 358

Bio Pharma Dive

JUNE 29, 2021

A merger with Foresite Capital's blank-check company makes Pardes Biosciences the latest well-funded drugmaker pursuing development of an oral coronavirus antiviral.

Development 171

Development 171

Bio Pharma Dive

FEBRUARY 16, 2024

The FDA paused enrollment in the only remaining tests of the drug, as Gilead reviews the program it acquired through a buyout of biotech Forty Seven.

Drugs 177

Drugs 177

Fierce Pharma

JANUARY 30, 2024

How will it fare in latest round of GSK showdown? After 'bad launch' remark by CEO, Pfizer's RSV vaccine gains traction in Q4. kdunleavy Tue, 01/30/2024 - 08:58

Vaccination 126

Vaccination Vaccine 126

pharmaphorum

OCTOBER 27, 2023

Aiolos $245m Series A heads latest crop of biotech rounds Phil.Taylor Fri, 27/10/2023 - 14:41 Bookmark this

104

104

Drug Channels

FEBRUARY 7, 2024

The boffins at the Centers for Medicare & Medicaid Services (CMS) recently dropped the latest National Health Expenditure (NHE) data, which measures all U.S. spending on healthcare. Links below.) As you will see, retail and mail prescription drug spending remain a consistently small share of the $4.5 trillion that we spend on U.S.

Drugs 93

Drugs Branding Trials 93

Bio Pharma Dive

OCTOBER 28, 2022

After a slow start, Gilead’s CAR-T business is growing fast, enabling it to pull ahead of rival cell therapy developers like Bristol Myers Squibb and Johnson & Johnson.

Sales 339

Sales Development 339

Bio Pharma Dive

NOVEMBER 30, 2022

The richly funded drugmaker will cut 15% of its workforce, or about 75 employees, as well as stop work on one of its preclinical research programs.

Drugs 335

Drugs Research 335

pharmaphorum

JULY 27, 2023

Medicxi primes its latest $400m biotech fund Phil.Taylor Thu, 27/07/2023 - 08:09 Bookmark this

98

98

Bio Pharma Dive

APRIL 4, 2023

Hiring Adam Keeney, a Sanofi veteran, to lead corporate development could be seen as timely, given that dealmaking has come into focus at Biogen since the recent appointment of Chris Viehbacher as CEO.

Development 263

Development 263

Bio Pharma Dive

MARCH 6, 2024

The Barcelona-based firm, which is targeting about €100 million for the new fund, is eyeing investments in AI, synthetic biology, and cell and gene therapy.

Gene Therapy 156

Gene Therapy Gene 156

pharmaphorum

JUNE 6, 2023

Eisai is latest pharma to suffer ransomware attack Phil.Taylor Tue, 06/06/2023 - 09:07 Bookmark this

105

105

Bio Pharma Dive

OCTOBER 5, 2023

The company exercised an option to buy Mitokinin, a Pfizer-backed drugmaker built on work by scientific co-founders Nicholas Hertz and Kevan Shokat.

Drugs 177

Drugs 177

Bio Pharma Dive

AUGUST 15, 2023

San Diego-based Tentarix will receive $66 million in cash and equity from Gilead, which holds an option to acquire up to three of the company’s subsidiaries.

Research 242

Research Drugs 242

Bio Pharma Dive

MARCH 15, 2022

Stung by a stock market downturn, a number of biotechs are trimming spending and reprioritizing research to save cash. Passage's layoffs will reduce its workforce by 13%.

Marketing 310

Marketing Research 310

Drug Discovery World

DECEMBER 21, 2023

This is the latest episode of the free DDW narrated podcast, titled “Where is the latest innovation in neuroscience?” The post Where is the latest innovation in neuroscience? which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. appeared first on Drug Discovery World (DDW).

Development 52

Development Drugs Production Research 52

pharmaphorum

AUGUST 14, 2023

Ultragenyx is latest biotech sued over HeLa cell use Phil.Taylor Mon, 14/08/2023 - 07:03 Bookmark this

98

98

Bio Pharma Dive

APRIL 17, 2023

The buyout of Prometheus highlights pharmaceutical companies’ intense interest in medicines targeting inflammatory diseases, according to analysts.

Medicine 286

Medicine 286

Bio Pharma Dive

OCTOBER 25, 2021

The FDA has approved Susvimo, a device that continuously administers a version of Roche's Lucentis over several months. It could challenge Regeneron's top-selling drug.

Drugs 299

Drugs 299

Pharmaceutical Technology

APRIL 24, 2024

Pfizer and its Germany partner BioNTech have urged London’s High Court to invalidate competitor Moderna's patents over technology instrumental in the Covid-19 vaccines development as the latest phase of a global legal fight that started yesterday (23 April), reported Reuters.

Vaccination 325

Vaccination Vaccine Development 325